Skip to content

A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study of Batoclimab Treatment in Adult Participants with Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Status
Suspended
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-512646-42-00
Acronym
IMVT-1401-2401
Enrollment
178
Registered
2024-08-27
Start date
2023-06-27
Completion date
Unknown
Last updated
2025-10-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Brief summary

Period 2 / Cohort A: Proportion of participants who remain relapse-free at Week 36 where relapse is defined as a worsening (increase) of ≥ 1 point on the Adj INCAT score at any time point during Period 2 relative to Period 2 baseline which is sustained at a Follow-Up visit 1 week later.

Detailed description

Period 2 / Cohort A: -Time to first relapse relative to Period 2 baseline - Change from Period 2 baseline to Week 36 in: Adj INCAT score, Inflammatory Rasch-built Overall Disability Scale (I-RODS), Mean Grip Strength, Medical Research Council (MRC) Sum Score, Overall Neuropathy Limitations Scale (ONLS), Period 2 / Cohort A and B combined: Change from Period 2 baseline to Week 36 in: Adj INCAT score, I-RODS, Mean Grip Strength, MRC Sum Score, ONLS, Period 2 / Cohorts A, B and C combined: Proportion of participants who remain relapse-free at Week 36.

Interventions

Sponsors

Immunovant Sciences GmbH
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Period 2 / Cohort A: Proportion of participants who remain relapse-free at Week 36 where relapse is defined as a worsening (increase) of ≥ 1 point on the Adj INCAT score at any time point during Period 2 relative to Period 2 baseline which is sustained at a Follow-Up visit 1 week later.

Secondary

MeasureTime frame
Period 2 / Cohort A: -Time to first relapse relative to Period 2 baseline - Change from Period 2 baseline to Week 36 in: Adj INCAT score, Inflammatory Rasch-built Overall Disability Scale (I-RODS), Mean Grip Strength, Medical Research Council (MRC) Sum Score, Overall Neuropathy Limitations Scale (ONLS), Period 2 / Cohort A and B combined: Change from Period 2 baseline to Week 36 in: Adj INCAT score, I-RODS, Mean Grip Strength, MRC Sum Score, ONLS, Period 2 / Cohorts A, B and C combined: Proportion of participants who remain relapse-free at Week 36.

Countries

Belgium, Bulgaria, Denmark, Finland, Germany, Greece, Italy, Norway, Poland, Portugal, Romania, Slovakia, Spain, Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026